New Jersey 2022-2023 Regular Session

New Jersey Senate Bill S307

Introduced
1/11/22  

Caption

Authorizes expanded provision of harm reduction services to distribute sterile syringes and provide certain support services to persons who use drugs intravenously; appropriates $15 million.

Impact

The passage of SB 307 would amend existing laws surrounding harm reduction strategies, allowing for broader access to services aimed at reducing the spread of bloodborne infections and overdose rates among intravenous drug users. By facilitating syringe access and providing support services, the bill aims to mitigate the health risks associated with drug use while promoting community health and safety. Moreover, the bill emphasizes municipal involvement, requiring the Department of Health to engage local leaders in the planning and implementation of services, fostering cooperation between state health initiatives and community needs.

Summary

Senate Bill 307 proposes an expansion of harm reduction services aimed at addressing public health issues related to intravenous drug use in New Jersey. The bill authorizes the distribution of sterile syringes and related support services, such as HIV and hepatitis C testing, referrals to health and social services, and overdose prevention initiatives. An appropriation of $15 million is included to support these efforts, with $5 million designated for the Department of Health to facilitate harm reduction services and $10 million for the Division of Mental Health and Addiction Services to enhance treatment availability.

Contention

There are some expectations of contention surrounding SB 307, primarily revolving around concerns regarding the potential normalization of drug use and the effectiveness of harm reduction strategies. Critics may argue that providing access to sterile syringes could inadvertently encourage substance abuse behaviors rather than alleviate them. Supporters, on the other hand, counter that the bill is grounded in extensive research demonstrating the benefits of harm reduction services in decreasing disease transmission and overdoses without increasing drug usage rates. This ongoing debate illustrates the challenge of balancing public health interventions with societal perceptions of drug use.

Companion Bills

No companion bills found.

Previously Filed As

NJ S4017

Requires DOH to purchase xylazine test strips to be distributed to entities that provide authorized harm reduction services; makes appropriation.

NJ S2569

Provides that persons between 18 and 21 years of age with disabilities are eligible to receive direct support professional services from DHS.

NJ A1789

Provides that sterile syringe access programs are inherently beneficial uses.

NJ S2435

Provides for certain pediatric NJ FamilyCare beneficiaries to maintain private duty nursing hours when transitioning to Managed Long Term Services and Supports; codifies and expands appeals provisions for private duty nursing services.

NJ S2874

Requires provision of trauma-informed reentry support services to certain defendants who are victims of abuse.

NJ A4080

Provides for certain pediatric NJ FamilyCare beneficiaries to maintain private duty nursing hours when transitioning to Managed Long Term Services and Supports; codifies and expands appeals provisions for private duty nursing services.

NJ S2583

Requires minimum annual State appropriation of $10 million for Public Health Priority Funding.

NJ S2630

Requires Director of Division of Local Government Services in DCA to establish grant program to enhance local government efficiency; appropriates $1.5 million.

NJ S1173

Expands NJT Access Link paratransit service area to include certain veterans health care facilities; appropriates $1 million.

NJ S4328

Appropriates funds up to $25 million for distribution to certain school districts to support health care cost increases.

Similar Bills

No similar bills found.